BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17631559)

  • 41. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors.
    Uematsu H; Sadato N; Ohtsubo T; Tsuchida T; Nakamura S; Sugimoto K; Waki A; Takahashi N; Yonekura Y; Tsuda G; Saito H; Hayashi N; Yamamoto K; Ishii Y
    J Nucl Med; 1998 Mar; 39(3):453-9. PubMed ID: 9529291
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG.
    Beer AJ; Lorenzen S; Metz S; Herrmann K; Watzlowik P; Wester HJ; Peschel C; Lordick F; Schwaiger M
    J Nucl Med; 2008 Jan; 49(1):22-9. PubMed ID: 18077538
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 18F-FDG small-animal PET for monitoring the therapeutic effect of CT-guided radiofrequency ablation on implanted VX2 lung tumors in rabbits.
    Okuma T; Matsuoka T; Okamura T; Wada Y; Yamamoto A; Oyama Y; Koyama K; Nakamura K; Watanabe Y; Inoue Y
    J Nucl Med; 2006 Aug; 47(8):1351-8. PubMed ID: 16883016
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
    Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
    Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors.
    Otomi Y; Otsuka H; Morita N; Terazawa K; Furutani K; Harada M; Nishitani H
    J Med Invest; 2010 Aug; 57(3-4):270-4. PubMed ID: 20847527
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 68Ga-FAPI-04 PET/CT Versus 18F-FDG PET/CT in the Detection of Malignant Gastrointestinal Stromal Tumor.
    Zhang Z; Jiang H; Zhang L; Cheng C; Zuo C
    Clin Nucl Med; 2023 Jan; 48(1):61-63. PubMed ID: 36469061
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
    Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
    J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG.
    Cook GJ; Houston S; Barrington SF; Fogelman I
    J Nucl Med; 1998 Jan; 39(1):99-103. PubMed ID: 9443745
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET.
    Higashi T; Sakahara H; Torizuka T; Nakamoto Y; Kanamori S; Hiraoka M; Imamura M; Nishimura Y; Tamaki N; Konishi J
    J Nucl Med; 1999 Sep; 40(9):1424-33. PubMed ID: 10492360
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Correlation of measurements from diffusion weighted MR imaging and FDG PET/CT in GIST patients: ADC versus SUV.
    Wong CS; Gong N; Chu YC; Anthony MP; Chan Q; Lee HF; Chu KM; Khong PL
    Eur J Radiol; 2012 Sep; 81(9):2122-6. PubMed ID: 21955604
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ¹⁸F-FDG PET/CT and contrast enhanced CT in differential diagnosis between leiomyoma and gastrointestinal stromal tumor.
    Hirose Y; Kaida H; Kawahara A; Kurata S; Ishibashi M; Abe T
    Hell J Nucl Med; 2015; 18(3):257-60. PubMed ID: 26574696
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy.
    Paudyal B; Oriuchi N; Paudyal P; Tsushima Y; Iida Y; Higuchi T; Hanaoka H; Miyakubo M; Takano A; Ishikita T; Endo K
    Oncol Rep; 2007 Dec; 18(6):1469-73. PubMed ID: 17982632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early response evaluation using 18F-FDG-PET/CT does not influence management of patients with metastatic gastrointestinal stromal tumors (GIST) treated with palliative intent.
    Farag S; IJzerman NS; Houdijk MPM; Reyners AKL; Arens AI; Grünhagen DJ; Desar IME; Gelderblom H; Steeghs N; de Geus-Oei LF
    Nuklearmedizin; 2021 Dec; 60(6):411-416. PubMed ID: 34479374
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.
    Nuñez R; Macapinlac HA; Yeung HW; Akhurst T; Cai S; Osman I; Gonen M; Riedel E; Scher HI; Larson SM
    J Nucl Med; 2002 Jan; 43(1):46-55. PubMed ID: 11801702
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas.
    Henze M; Schuhmacher J; Hipp P; Kowalski J; Becker DW; Doll J; Mäcke HR; Hofmann M; Debus J; Haberkorn U
    J Nucl Med; 2001 Jul; 42(7):1053-6. PubMed ID: 11438627
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 68Ga-DOTATATE PET/CT for the detection of inflammation of large arteries: correlation with18F-FDG, calcium burden and risk factors.
    Li X; Samnick S; Lapa C; Israel I; Buck AK; Kreissl MC; Bauer W
    EJNMMI Res; 2012 Sep; 2(1):52. PubMed ID: 23016793
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
    Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
    J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preoperative assessment of malignant potential of gastrointestinal stromal tumor by dual-time-point 18F-fluorodeoxyglucose positron emission tomography imaging: Usefulness of standardized uptake value and retention index.
    Kwon Y; Park E; Pahk K; Kim S; Kim MJ; Graf D; Park S
    J Cancer Res Ther; 2019; 15(1):142-147. PubMed ID: 30880770
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical applications of 18F-fluorodeoxyglucose positron emission tomography in gastrointestinal stromal tumor of the esophagus.
    Sakai M; Kato H; Saito K; Tanaka N; Inose T; Kimura H; Miyazaki T; Kuwano H
    Int Surg; 2008; 93(4):209-13. PubMed ID: 19731855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.